Axsome Therapeutics, Inc. (AXSM) income statement
AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$135.68+1.68 (+1.25%)
Close on Nov 19, 2026Market cap $7.11BP/E –Yield –
Axsome Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 93.2%
- Operating margin
- -24.0%
- Net margin
- -24.7%
- Return on equity, FY2025
- -252.1%
Financial strength
- Current ratio
- 1.43
- Debt to equity
- 2.26
- Debt to assets
- 24.7%
- Cash to current liabilities
- 69.5%
Valuation
- P/E ratio
- –
- Price to sales
- 9.15
- Price to book
- 85.31
- Dividend yield
- –
See a number that looks wrong?